BKD Wealth Advisors LLC raised its position in Amgen Inc. (NASDAQ:AMGN) by 2.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,580 shares of the medical research company’s stock after purchasing an additional 91 shares during the quarter. BKD Wealth Advisors LLC’s holdings in Amgen were worth $617,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. TrimTabs Asset Management LLC increased its stake in shares of Amgen by 88.9% during the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after acquiring an additional 288 shares during the period. Alpha Omega Wealth Management LLC increased its stake in shares of Amgen by 19.0% during the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after acquiring an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. increased its stake in shares of Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after acquiring an additional 4 shares during the period. American Beacon Advisors Inc. acquired a new position in shares of Amgen during the first quarter valued at approximately $106,000. Finally, Nelson Roberts Investment Advisors LLC acquired a new position in shares of Amgen during the first quarter valued at approximately $121,000. Institutional investors own 78.09% of the company’s stock.

WARNING: “BKD Wealth Advisors LLC Has $617,000 Holdings in Amgen Inc. (AMGN)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/bkd-wealth-advisors-llc-has-617000-holdings-in-amgen-inc-amgn/1576174.html.

A number of research analysts recently commented on AMGN shares. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $189.00 price objective on shares of Amgen in a research note on Friday, June 30th. BidaskClub upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Credit Suisse Group set a $177.00 price objective on shares of Amgen and gave the company a “hold” rating in a research note on Friday, July 14th. Morgan Stanley raised their price objective on shares of Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, June 13th. Finally, Deutsche Bank AG reiterated a “hold” rating and set a $174.00 price objective (up previously from $172.00) on shares of Amgen in a research note on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $186.14.

Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.53% during midday trading on Wednesday, hitting $187.30. 706,573 shares of the company’s stock were exchanged. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $191.10. The company has a 50-day moving average of $175.99 and a 200-day moving average of $169.31. The firm has a market cap of $136.67 billion, a price-to-earnings ratio of 17.06 and a beta of 1.35.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.84 earnings per share. Equities research analysts expect that Amgen Inc. will post $12.57 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were issued a $1.15 dividend. This represents a $4.60 annualized dividend and a dividend yield of 2.47%. The ex-dividend date was Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 41.93%.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.